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Background and aims: The OCTN1 (SLC22A4 1672CRT) and OCTN2 (SLC22A5 2207GRC) variants
within the IBD5 locus have been associated with susceptibility to adult onset Crohn’s disease (CD), but their
contribution in children has not been examined.
Methods: These OCTN1/2 variants and IBD5 marker single nucleotide polymorphisms (SNPs)
(IGR2096a_1, IGR2198a_1, and IGR2230a_1) were examined in 299 Scottish children (200 with CD,
74 with ulcerative colitis (UC), and 25 with indeterminate colitis (IC)), together with 502 parents (for
transmission disequilibrium testing) and 256 controls.
Results: All SNPs were in strong linkage disequilibrium (D9 .0.94). TDT analysis showed association of the
OCTN1 variant with inflammatory bowel disease (IBD) (p = 0.01) and CD (p = 0.04). Allele frequencies of
the OCTN1/2 variants were significantly higher in IBD/CD cases (p,0.04). The homozygous mutant
OCTN1/2 haplotype was increased in IBD (24.3% v 16.1%, p = 0.02) and UC (28.2% v 16.1%, p = 0.02)
compared with controls. The OCTN1/2 variants were not independent of the background IBD5 risk
haplotype in conferring disease susceptibility. Unifactorial analysis in CD patients showed that carriage of
the TC haplotype was associated with lower weight, height, and BMI centile (,9th centile) at diagnosis
(weight: 87.9% v 67.3% (p = 0.002), odds ratio (OR) = 3.52 (95% confidence interval, 1.51 to 8.22);
height: 84.1% v 68.4% (p,0.05), OR = 2.44 (1.00 to 5.99); BMI: 79.6% v 61.1% (p = 0.02), OR = 2.49
(1.14 to 5.44)), and lower weight centile at follow up (87.5% v 64.6% (p = 0.03), OR = 3.83 (1.03 to
14.24)). Multifactorial binary logistic regression analysis confirmed association of the TC haplotype with
lower weight centile at diagnosis (p = 0.02, OR = 3.41 (1.20 to 9.66)).
Conclusions: These data implicate variants within the IBD5 haplotype, as determinants of disease
susceptibility and growth indices in early onset IBD. The OCTN1/2 variants remain potential positional
candidate genes, but require further analysis.
T
he inflammatory bowel diseases (IBD) are chronic
relapsing inflammatory conditions affecting the gastro-
intestinal tract, comprising Crohn’s disease (CD), ulcera-
tive colitis (UC), and indeterminate colitis (IC). The aetiology
of IBD is unknown, although there is strong evidence for a
gene–environment interaction.1 Around 15–25% of cases will
present in childhood.2 The incidence of paediatric IBD in
Scotland is higher than elsewhere in the United Kingdom
and has increased threefold in the past 30 years.3–5
IBD starting in childhood can have profound effects on a
child’s growth, pubertal development, and education. Growth
failure is a common feature of childhood IBD, particularly in
Crohn’s disease.6 Several factors have been linked to growth
failure in Crohn’s disease including delay to diagnosis,7
jejunal inflammation,8 disease severity,9 age at diagnosis,10
and genotype.11
Genome-wide scanning in IBD has identified various
susceptibility loci, with two that are particularly noteworthy
in early onset disease—IBD1 and IBD5.12 The contribution of
the NOD2/CARD15 gene to genetic susceptibility to Crohn’s
disease varies between populations. In Scotland and northern
Europe this effect is significantly less strong than in many
other paediatric and adult IBD populations.13
The IBD5 locus (5q31–33) was first identified in genome-
wide scanning of North American Crohn’s disease
patients.14 15 Rioux et al stratified the genetic data from the
Canadian genome-wide scan by age, and showed that the
highest LOD (log of odds) score was found in patients with
Crohn’s disease diagnosed under 16 years of age.14
In a detailed study of the IBD5 locus, Daly and colleagues
reported strong linkage disequilibrium across the region, and
derived a risk haplotype for Crohn’s disease that as
represented by 11 marker single nucleotide polymorphisms
(SNPs) in separate haplotype blocks that spanned the whole
250 kb interval.16 Heterozygotes for the IBD5 risk haplotype
had a twofold increased risk of Crohn’s disease, and
homozygotes a sixfold increase, but with no increased risk
of ulcerative colitis.17 Several European studies have now
replicated the association of IBD5 with susceptibility to adult
onset Crohn’s disease,18–21 and additionally one study has
shown an association with ulcerative colitis.18 Genotype–
phenotype studies in adult onset disease have shown
association with perianal Crohn’s disease20 and earlier age
of disease onset.19 IBD5 epistasis has been demonstrated with
the IBD6 locus22 and with NOD2/CARD15, for both Crohn’s
disease19 and ulcerative colitis.18 23
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease;
IC, indeterminate colitis; SNP, single nucleotide polymorphism; UC,
ulcerative colitis
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Two variants within the IBD5 interval have been suggested
to be independently associated with Crohn’s disease; variant
alleles of the OCTN1 gene (SLC22A4 C/T, missense mutation)
and OCTN2 (SLC22A5 2207 G/C, promoter mutation).24 Both
of these genes have been suggested to play a role in carnitine
transport but critical expression and functional data in IBD
patients are still awaited. In the initial publication from
Peltekova and colleagues, the resulting two allele risk (TC)
haplotype was independently associated with susceptibility to
Crohn’s disease when Crohn’s disease patients and controls
who were homozygous wild type for marker SNP IGR2078a_1
were compared.24 Moreover, several subsequent adult studies
have been unable to confirm that the OCTN1/2 effect is
independent of the other potential determinants within the
extended IBD5 haplotype.25 26
In this study we have analysed the contribution to disease
susceptibility and phenotype of three markers on the IBD5
haplotype, together with the OCTN1/2 variants and the TC
haplotype within a large homogenous paediatric IBD popula-
tion. We have specifically examined whether the OCTN1/2
effect is independent of other determinants within the IBD5
locus. In addition our detailed phenotypic data have allowed us
to examine the effect of these markers on growth indices.
METHODS
Patients
We recruited 299 patients with IBD diagnosed at less than 16
years of age from Scottish paediatric gastroenterology centres
and from the Western General Hospital, Edinburgh. Two
hundred patients had an established diagnosis of Crohn’s
disease, 74 ulcerative colitis, and 25 indeterminate colitis.
Parents and controls
We also enrolled 502 parents to construct family trios for
transmission disequilibrium testing (TDT) (71% of the
patients had complete family trios). DNA from 256 healthy
adult controls was also available for case–control analysis.26
Disease phenotype
Standardised criteria were used for IBD diagnosis.27 A patient
was categorised as having ‘‘indeterminate colitis’’ if definite
evidence of chronic inflammatory bowel disease affecting the
colon only was present, but the patient remained unclassifi-
able as either Crohn’s disease or ulcerative colitis after
considering all clinical, radiological, endoscopic, and patho-
logical findings. The location and behaviour of Crohn’s
disease was assessed at the time of diagnosis and at two
yearly intervals after diagnosis, categorised using the Vienna
classification.28 Disease location in Crohn’s disease was also
categorised and analysed according to disease location
regardless of disease involvement elsewhere in the gastro-
intestinal tract, as previously described.13 The use of this
comprehensive complementary classification system over-
comes some of the recognised limitations of the Vienna
classification, notably the difficulties of categorising patients
with disease involving both the upper gastrointestinal tract
and other sites.29 In this classification, patients were
diagnosed with Crohn’s disease of the upper gastrointestinal
tract (oesophagus, stomach, and duodenum) when biopsies
from any of these sites confirmed the presence of epithelioid
granulomas (not merely in the presence of chronic inflam-
mation), or when features of macroscopic disease were
present,30–32 or both. Perianal disease was defined by the
presence of anal fissures, perianal abscesses, fistulae, and
perianal ulcers, consistent with recommendations of
Lennard-Jones et al.27 To allow comparison with the results
published by other groups,20 33 we also analysed data using
the more limited definition of perianal disease applied by
these investigators, who excluded anal fissures.
Data collection
Disease phenotype was determined using a combination of
patient questionnaire, interview, and retrospective case note
review, as previously described.13 Information collected
included weight, height, and body mass index (BMI) values,
which were plotted on a centile chart (E Child Growth
Foundation, 1996) and an appropriate centile band allocated.
Table 1 Demographic variables at the time of diagnosis
in the Crohn’s disease patients included in the study
Sex (M/F) 121/79
Median age at diagnosis (y) 11.2 (IQR 8.6 to 13.0)
Current smoker 3 (2%)
Family history 68 (34%)
White (%) 195 (97%)
Location according to the Vienna
classification28
Terminal ileum (L1) 9 (4.6%)
Colon (L2) 48 (24.4%)
Ileocolon (L3) 38 (19.2%)
Upper gastrointestinal (L4) 93 (47.2%)
None* 9 (4.6%)
Behaviour according to the Vienna
classification28
Inflammatory (B1) 163 (82.7%)
Stricturing (B2) 7 (3.6%)
Penetrating (B3) 27 (13.7%)
Disease location
Oral 27/182 (14.8%)
Oesophageal 7/170 (4.1%)
Gastric antrum 49/168 (29.2%)
Gastric body 32/167 (19.1%)
Duodenal 26/167 (15.6%)
Jejunal 29/165 (17.6%)
Ileal 111/173 (64.2%)
Caecal 108/142 (76.0%)
Ascending 110/146 (75.3%)
Transverse 119/156 (76.3%)
Descending 125/167 (77.1%)
Sigmoid 137/174 (78.7%)
Rectal 139/182 (76.4%)
Perianal` 80/190 (42.1%)
Perianal1 20/190 (10.5%)
Anthropometry
Weight ,9th centile 71/185 (38.4%)
Weight ,25th centile 104/185 (56.2%)
Height ,9th centile 46/178 (25.8%)
Height ,25th centile 83/178 (46.6%)
BMI ,9th centile 66/178 (37.1%)
BMI ,25th centile 92/178 (51.7%)
Mean weight z score (SD) 20.68 (1.55)
Mean height z score (SD) 20.48 (2.01)
Mean BMI z score (SD) 0.66 (1.60)
Associated diseases
Asthma 58/198 (29.3%)
Eczema 68/198 (34.3%)
Hayfever 41/198 (20.7%)
All three diseases 15/198 (7.9%)
The phenotypic data at diagnosis are based on 197 Crohn’s disease
patients unless otherwise stated.
*These were patients who fulfilled the diagnostic criteria for Crohn’s
disease but whose disease location does not allow the use of the Vienna
classification; all had perianal or oral Crohn’s disease or both without
evidence of disease elsewhere in the gastrointestinal tract.
The presence or absence of evidence for Crohn’s disease activity in each
location was based on evidence from endoscopy, biopsy, or barium
follow through and was independent of disease activity elsewhere in the
gastrointestinal tract.
`Perianal disease was defined by the presence of fissures, perianal
ulcers, abscesses, or fistulae but not by the presence of skin tags alone.
1Perianal disease was defined by the presence perianal ulcers,
abscesses, or fistulae but not by the presence of skin tags or fissures.
Based on centile plotted on UK Growth Chart (E Child Growth
Foundation, 1996).
BMI, body mass index; IQR, interquartile range; y, years.
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Each patient had their height measured on a wall mounted
stadiometer. Anthropometric data were also defined using
z scores. A z score for a growth parameter indicates how far
and in what direction that item deviates from its distribu-
tion’s mean, expressed in units of its distribution’s standard
deviation. The demographics details of the patients with
Crohn’s disease and ulcerative colitis in the study are shown
in tables 1 and 2, respectively.
Ethical approval was given for all participating centres. All
families gave informed written consent before participation
in the study.
Genotyping
Genomic DNA was extracted from blood using a modified
salting-out technique,34 and resuspended in 16TE (10 mM
Tris (pH 8.0), 1 mEDTA (pH 8.0)) at a final concentration of
100 ng/ml. Three marker SNPs on the IBD5 haplotype were
typed IGR2096a_1, IGR2198a_1, and IGR2230a_1. The
rs1050152 polymorphism of the OCTN1 gene (SCL22A4 exon
9 1672CRT) and the rs26313667 (SLC22A5 promoter,
2207GRC) polymorphism of the OCTN2 gene were also
typed. The primers used in the study are given in table 3.
The relative positions of these markers within the
haplotype blocks described by Daly et al are shown in fig 1.
All genotyping was carried out using the TaqMan system
(EBiosystems). The three NOD2/CARD15 mutations
(Leu1007InsC, G908R, and R702W) were genotyped as
previously described.35
Statistical analysis
Each of the five SNPs was analysed individually using allele
frequencies and carriage rates for association with IBD,
Crohn’s disease, and ulcerative colitis. As the total number of
patients with indeterminate colitis was small these data were
included in IBD analysis overall and were not analysed as an
individual disease group. TDT analysis was carried out using
Transmit (version 2.5)36 after the Pedcheck software program
was used to exclude any potential cases of non-paternity or
genotyping error.37 Genotype–phenotype relations were
determined by x2 or Fisher’s exact test using Minitab v.13
(Minitab Ltd, Coventry, UK). Multifactorial analysis was
done using binary logistic regression analysis. Haplotypes
were calculated using Haploview, v.3.2. All SNPs in patients
and controls were in Hardy–Weinberg equilibrium. We
calculated z scores using a program designed by Dr C
Wright (Glasgow University) and values were compared by
the Mann–Whitney test. Odds ratios (OR) and 95% con-
fidence intervals (CI) are given.
RESULTS
Strong linkage disequilibrium was seen between the three
IBD5 haplotype SNPs and the two OCTN variants (fig 2). The
pairwise D9 scores for all five markers were 0.94 or above.
Transmission disequilibrium testing analysis
These results are shown in table 4. The IGR2198a_1 allele was
associated with susceptibility to IBD (p = 0.02).
Homozygosity for the mutant IBD5 haplotype (patients who
were homozygous mutants for all three IBD5 haplotype
marker variants IGR2096a_1, IGR2198a_1, and IGR2230a_1)
was associated with susceptibility to Crohn’s disease
(p,0.05). The OCTN1 variant was associated with suscept-
ibility to IBD and Crohn’s disease (p = 0.01 and p = 0.04,
respectively). The homozygous OCTN1/2 mutant haplotype
was associated with susceptibility to IBD (p = 0.01).
Case–control analysis
Inf lammatory bowel disease
The results are given in table 5. The allele frequencies were
significantly higher in IBD patients for all three IBD5 SNPs
and for the OCTN1/2 variants than in healthy controls
(p = 0.01 to 0.04). Homozygosity rates for the IBD5 variant
alleles IGR2096a_1 and IGR2198a_1, as well as homozygosity
rates for the mutant TC haplotype in patients with IBD, were
significantly higher than in healthy controls:
IGR2096a_1: 24.4% v 15.2% (p = 0.008), odds ratio
(OR) = 1.79 (1.16 to 2.78);
IGR2198a_1: 22.8% v 15.2% (p = 0.03), OR = 1.64 (1.06 to
2.54);
mutant TC haplotype: 24.3% v 16.1% (p = 0.02), OR = 1.67
(1.08 to 2.58).
Crohn’s disease
These results are shown in table 6. The frequencies of variant
alleles in Crohn’s disease patients compared with healthy
controls were significantly higher for the variants:
IGR2096a_1: 49.2% v 42.0% (p = 0.04), OR = 1.34 (1.02 to
1.75);
IGR2198a_1: 47.7% v 41.0% (p = 0.04), OR = 1.31 (1.01 to
1.71);
Table 2 Demographic variables at the time of diagnosis
in the ulcerative colitis patients included in the study
Sex (M/F) 32/37
Median age at diagnosis (y) 10.7 (IQR 8.5 to 12.9)
Current smoker 1 (1.4%)
Family history 20 (29.0%)
White (%) 66 (95.6%)
Disease extent
Pancolitis 36 (52.2%)
Extensive colitis* 13 (18.8%)
Left sided colitis 16 (23.2%)
Proctitis 4 (5.8%)
Colectomy (%)` 9/64 (14.1%)
Extraintestinal manifestations (%) 7/67 (10.4%)
Anthropometric measurements1
Weight ,9th centile 11/65 (16.9%)
Weight ,25th centile 20/65 (30.8%)
Height ,9th centile 9/59 (15.2%)
Height ,25th centile 23/59 (39.0%)
BMI ,9th centile 6/59 (10.2%)
BMI ,25th centile 19/59 (15.2%)
The data refer to 69 patients at disease diagnosis unless otherwise stated.
*Inflammation beyond the splenic flexure excluding patients with
pancolitis.
Inflammation distal to the splenic flexure excluding patients with
proctitis.
`The number of patients who had had a colectomy by the time of last
clinic follow up.
1Based on centile plotted on UK Growth Chart (E Child Growth
Foundation, 1996).
BMI, body mass index; IQR, interquartile range; y, years.
Table 3 Primers used to examine each of the five single
nucleotide polymorphisms involved in this study
IGR
TaqMan primersnumber
IGR2096 Forward: TCTGAGACAGGAGCCACTAGAG
Reverse: CACAGCATCCAGAGTGATCCT
IGR2198 Forward: GGGTTGCATGAGCATTAAGTTTCAA
Reverse: CCACATCAAGGATAAGACTGCTAAATACT
IGR2222 Forward: GCGGCTGGCCTTACATAGG
Reverse: CCGCTCTGCCTGCCA
IGR2230 Forward: GCAGGCAGAACAGCCATACT
Reverse: GGCCACAGAACTTTCATTAAAGTAGGA
IGR3002 Forward: TTTACAGGTGCTTACAACAGAATG
Reverse: TAGTCTGACTGTCCTGATTGGAATC
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OCTN2: 54.8% v 47.9% (p = 0.04), OR = 1.32 (1.01 to 1.72).
Homozygous carriage of mutant IGR2096a_1 was higher in
Crohn’s disease patients than in the controls, at 23.6% v
15.2% (p = 0.03), OR = 1.72 (1.06 to 2.79).
Ulcerative colit is
These results are shown in table 7. The frequency of the
IGR2198a_1 variant allele was higher in the patients with
ulcerative colitis than in the controls (50.7% v 41.0%
(p = 0.04), OR = 1.48 (1.02 to 2.15)). Homozygosity for the
variant alleles was higher in ulcerative colitis patients than
controls, as follows:
IGR2096a_1: 27.9% v 15.2% (p = 0.01), OR = 2.16 (1.15 to
4.05);
IGR2198a_1: 26.8% v 15.2% (p = 0.04), OR = 1.92 (1.03 to
3.58).
Homozygous carriage of the mutant TC haplotype and of a
combined IBD5 haplotype (homozygosity for all three IBD5
marker SNP variants) was also higher in patients with
ulcerative colitis than in controls:
mutant TC haplotype: 28.2% v 16.1% (p = 0.02), OR = 2.04
(1.10 to 3.78);
combined IBD5 haplotype: 26.6% v 14.7% (p = 0.02),
OR = 2.10 (1.09 to 4.05).
Association between the OCTN1/2 TC haplotype and
disease susceptibility
There was no independent association between the TC
haplotype and susceptibility to IBD, Crohn’s disease, or
ulcerative colitis in individuals lacking the extended IBD5
risk haplotype markers (IGR2198a_1, IGR2230a_1, and
IGR2096a_1) (table 8). The data shown in table 8 do not
show a significant differences between IBD, Crohn’s disease,
or ulcerative colitis compared with controls in the carriage of
the variant alleles representing the TC haplotype on a
background of having no IGR2198a_1 risk alleles. Thus for
Crohn’s disease only four of 47 patients carried the TC
haplotype but no IGR2198a_1 variants, compared with 10 of
82 IGR2198a_1 variant negative controls (p = 0.57). The
same lack of association was also seen with the TC haplotype
if either of the two other variants (IGR2230a_1 and
IGR2096a_1) was analysed similarly, or if all three IBD5
SNPs were combined (data available on request).
No independent effect was demonstrated if the OCTN
variants 1 and 2 were considered individually rather than as
the TC haplotype (data available on request).
Epistasis with NOD2/CARD15 mutations
There was no evidence of epistasis between IBD/CD patients
with regard to the TC haplotype and patients carrying the
common NOD2/CARD15 mutations (Leu1007InsC, G908R,
and R702W) in NOD2/CARD15 carriers v non-carriers for IBD
and Crohn’s disease (70.3% v 76.8% (p = 0.39) and 71.0% v
76.9% (p = 0.49), respectively).
Genotype–phenotype analysis: unifactorial analysis
For clarity, the results presented in the genotype–phenotype
analysis (table 9) describe associations with the TC haplotype
only, with the exception of growth indices. The phenotypic
associations with the TC haplotype generally reflected the
4 5 6 7
IGR 2078a_1 IGR 2096a_1
(rs12521868)
IGR 2198a_1
(rs11739135)
IGR 2222a_1
(rs26313667)
IGR 2230a_1
(rs17622208)
IGR 3002a_1
(rs1050152)
Figure 1 The relative position within
the haplotype blocks of the IBD5 locus
(as described by Daly et al16) of the five
single nucleotide polymorphisms (SNPs)
within the haplotype examined in this
study. Also shown is the marker SNP
IGR 2078a_1 examined in the study by
Peltekova et al.24 The corresponding rs
numbers are given below each SNP
examined in this study. In Daly’s
original study, 11 separate haplotype
blocks were described; the numbers
shown here are the ones referred to in
the original publication. IGR 2222a_1
refers to the OCTN2 variant
(2207GRC) and IGR 3002a_1 refers
to the OCTN1 variant (1672CRT).
A A A A A
1 2 3 4 5
0.471
C C C C C 0.427
A A C C A 0.047
C A C C C 0.016
97 98 99 95
97 99 96
2 31 4 5
98 95
94
Block 1 (108.3 kb)
20
96
21
98
O
C
TN
2
22
31
O
C
TN
1
A = wild type C = mutant
Figure 2 The D9 scores of the five single nucleotide polymorphisms studied across the IBD5 haplotype and the common haplotype frequencies.
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genotype–phenotype results for all SNPs analysed across the
IBD5 haplotype (all SNPs in close linkage disequilibrium).
Supplementary information on the IBD5 alleles and OCTN
variant alleles individually is available on request.
Growth indices
A comparison was made between lowest three (,9th) centile
groupings and the remaining seven (.9th) centiles for
weight, height, and BMI. Carriage of the TC haplotype was
more common in patients with lower weight, height, and
BMI than in those in higher centiles at diagnosis of Crohn’s
disease:
lower weight: 87.9% v 67.3% (p = 0.002), OR = 3.52 (1.51 to
8.22);
lower height: 84.1% v 68.4% (p,0.05), OR = 2.44 (1.00 to
5.99);
lower BMI: 79.6% v 61.1% (p = 0.02), OR = 2.49 (1.14 to
5.44).
Analysis using median z scores comparing homozygous
carriers of the TC haplotype with non-carriers confirmed a
significant difference between the groups in BMI (21.32 v
20.51, p = 0.03) and for weight (21.16 v 20.49, p = 0.05)
but not for height (p = 0.89).
At two year follow up the TC haplotype was more common
in lower than in higher weight centiles, at 87.5% v 64.6%
(p = 0.03), OR = 3.83 (1.03 to 14.24).
Carriage of the TC haplotype showed a significance
difference for weight centile (,25th centile v .25th centile):
83.0% v 65.8% (p = 0.01), OR = 2.54 (1.23 to 5.23) at
diagnosis; 88.9% v 58.5% (p = 0.002), OR = 5.68 (1.75 to
18.37) at the two year follow up.
Disease location
Homozygous carriage of the TC haplotype was associated
with gastric antral Crohn’s disease, when comparison was
made with patients assessed and found to have no antral
disease at diagnosis (36.7% v 14.2% (p = 0.006), OR = 3.51
(1.40 to 8.83)).
Asthma, eczema, hayfever, and atopy
Homozygosity for the TC haplotype was less often seen in
patients with asthma than in those without (11.5% v 26.9%
(p = 0.02), OR = 0.35 (0.14 to 0.90)); was less common in
patients with hayfever than in those without (7.5% v 27.0%
(p = 0.009), OR = 0.22 (0.06 to 0.75)); and was less common
in patients who had all three atopic diseases combined
Table 4 Transmission disequilibrium testing results for IBD5 and OCTN variants in
patients with inflammatory bowel disease
Mutation
IBD CD UC
x2 p Value x2 p Value x2 p Value
IGR2230a_1 2.42 0.12 0.87 0.35 2.00 0.16
IGR2198a_1 5.57 0.02 2.24 0.15 4.03 0.06
IGR2096a_1 2.34 0.16 1.11 0.32 1.36 0.24
IBD5 haplotype 10.59 0.05 10.13 ,0.05 4.07 0.42
OCTN1 7.54 0.01 4.21 0.04 3.54 0.06
OCTN2 1.57 0.23 0.47 0.52 1.54 0.18
TC haplotype 12.92 0.01 6.59 0.11 7.72 0.21
The results were based on 293 patients with IBD, together with one or both parents (the numbers of informative trios
were 271/197/74 for IBD/CD/UC, respectively). The results represented are for the allelic variants of the IBD5
marker single nucleotide polymorphisms IGR2096a_1, IGR2198a_1, and IGR2230a_1, the 1672CRT variant of
the OCTN1 gene, and the 2207GRC variant of the OCTN2 gene. The IBD5 haplotype in this table refers to the
homozygosity for mutants of IGR2096a_1, IGR2198a_1, and IGR2230a_1 combined; the TC haplotype refers to
homozygosity for the mutants of OCTN1/2 combined.
CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.
Table 5 Allele frequencies and carriage rates for variants in the IBD5 haplotype in
patients with inflammatory bowel disease compared with healthy controls
IBD patients (n = 299) v
p Value Odds ratiohealthy controls (n = 256)
Allelic frequency
IGR2096a_1 49.6% v 42.0% 0.01 1.36 (1.07 to 1.73)
IGR2198a_1 48.4% v 41.0% 0.01 1.35 (1.07 to 1.72)
IGR2230a_1 53.8% v 47.5% 0.04 1.29 (1.01 to 1.64)
OCTN 1 50.0% v 42.9% 0.02 1.33 (1.05 to 1.69)
OCTN 2 54.5% v 47.9% 0.03 1.30 (1.03 to 1.66)
Homozygous carriage
IGR2096a_1 24.4% v 15.2% 0.008 1.79 (1.16 to 2.78)
IGR2198a_1 22.8% v 15.2% 0.03 1.64 (1.06 to 2.54)
IGR2230a_1 27.0% v 21.2% 0.12 1.38 (0.92 to 2.05)
TC haplotype 24.3% v 16.1% 0.02 1.67 (1.08 to 2.58)
Combined IBD5 carriage 21.3% v 14.7% 0.06 1.57 (0.99 to 2.49)
Three marker single nucleotide polymorphisms (SNPs) (IGR2096a_1, IGR2198a_1, and IGR2230a_1) were used
to represent the IBD5 haplotype together with two SNPs in the OCTN1 and 2 (1672CRT and 2207GRC,
respectively). All five SNPs were associated with susceptibility to inflammatory bowel disease (IBD). Homozygous
carriage of IGR2096a_1, IGR2198a_1, and the TC haplotype were associated with susceptibility to IBD. The results
for heterozygous carriage all failed to achieve significance (results not shown).
IBD, inflammatory bowel disease.
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(asthma, eczema, and hayfever) than in those without (0% v
25.3% (p = 0.02)).
Disease behaviour and need for surgery
At Crohn’s disease diagnosis and at the most recent follow up
no association was seen between carriage of the TC haplotype
and disease behaviour. During the period of analysis 26.9% of
patients underwent abdominal surgery for Crohn’s disease.
Carriage of the TC haplotype was no higher in those patients
needing surgery than those who did not (77.6% v 73.9%
(p = 0.61)).
Age at diagnosis
The median age at diagnosis of carriers of the TC haplotype
was 11.6 years (v 10.9 years for non-carriers (p = 0.12)) and
for TC homozygotes it was 12.1 years (v 11.3 years in non-
carriers (p = 0.06)).
Other phenotypic variables
No association was seen with the TC haplotype and family
history of IBD, extraintestinal manifestations, granulomas, or
blood test abnormalities (full blood count, erythrocyte
sedimentation rate, C reactive protein, or albumin concen-
tration).
Ulcerative colitis
Carriers of the TC haplotype were more common in patients
in lower height centiles at diagnosis (,25th centile v .25th
centile: 85.7% v 55.9% (p = 0.02), OR = 4.74 (1.17 to 19.16))
and showed a trend towards significance for weight centile
(83.3% v 59.5% (p = 0.07), OR = 3.40 (0.85 to 13.57)).
Genotype–phenotype analysis in this group was limited by
the small number of patients available for analysis (n = 69).
No relations were found between the TC haplotype and age at
diagnosis, extraintestinal manifestations, IBD family history,
need for surgery, and extent of disease (data not shown).
Multifactorial analysis
Using multifactorial binary logistic regression considering the
weight centile as either less than or more than the 9th centile,
disease location and behaviour as defined by the Vienna
classification, family history of IBD, erythema nodosum, and
Table 6 Allele frequencies and carriage rates for variants in the IBD5 haplotype in
Crohn’s disease patients compared with healthy controls
CD patients (n = 200) v
p Value Odds ratiohealthy controls (n = 256)
Allelic frequency
IGR2096a_1 49.2% v 42.0% 0.04 1.34 (1.02 to 1.75)
IGR2198a_1 47.7% v 41.0% 0.04 1.31 (1.01 to 1.71)
IGR2230a_1 53.8% v 47.5% 0.06 1.29 (0.99 to 1.69)
OCTN 1 49.5% v 42.9% 0.05 1.30 (1.00 to 1.70)
OCTN 2 54.8% v 47.9% 0.04 1.32 (1.01 to 1.72)
Homozygous carriage
IGR2096a_1 23.6% v 15.2% 0.03 1.72 (1.06 to 2.79)
IGR2198a_1 20.8% v 15.2% 0.12 1.46 (0.90 to 2.38)
IGR2230a_1 26.9% v 21.2% 0.16 1.37 (0.88 to 2.14)
TC haplotype 22.2% v 16.1% 0.11 1.48 (0.91 to 2.40)
Combined IBD5 haplotype 19.2% v 14.7% 0.42 1.38 (0.82 to 2.32)
Three marker single nucleotide polymorphisms (SNPs) (IGR2096a_1, IGR2198a_1, and IGR2230a_1) were used
to represent the IBD5 haplotype together with two SNPs in the OCTN1 and 2 (1672CRT and 2207GRC,
respectively). The three SNPs IGR2096a_1, IGR2198a_1, and 2207GRC were associated with susceptibility to
Crohn’s disease. Homozygous carriage of the IGR2096a_1 was also associated with susceptibility to Crohn’s
disease. The results for heterozygous carriage all failed to achieve significance (results not shown).
CD, Crohn’s disease.
Table 7 Allele frequencies and carriage rates for variants in the IBD5 haplotype in
patients with ulcerative colitis compared with healthy controls
Allelic frequency
UC patients (n = 74) v
p Value Odds ratiohealthy controls (n = 256)
IGR2096a_1 50.7% v 42.0% 0.07 1.42 (0.97 to 2.08)
IGR2198a_1 50.7% v 41.0% 0.04 1.48 (1.02 to 2.15)
IGR2230a_1 52.9% v 47.5% 0.25 1.24 (0.85 to 1.81)
OCTN1 52.1% v 42.9% 0.05 1.45 (1.00 to 2.10)
OCTN2 54.1% v 47.9% 0.18 1.28 (0.89 to 1.86)
Homozygous carriers
IGR2096a_1 27.9% v 15.2% 0.01 2.16 (1.15 to 4.05)
IGR2198a_1 26.8% v 15.2% 0.04 1.92 (1.03 to 3.58)
IGR2230a_1 27.5% v 21.2% 0.26 1.41 (0.77 to 2.60)
TC Haplotype 28.2% v 16.1% 0.02 2.04 (1.10 to 3.78)
Combined IBD5 haplotype 26.6% v 14.7% 0.02 2.10 (1.09 to 4.05)
Three marker single nucleotide polymorphisms (SNPs) (IGR2096a_1, IGR2198a_1, and IGR2230a_1) were used
to represent the IBD5 haplotype together with two SNPs in the OCTN1 and 2 (1672CRT and 2207GRC,
respectively). The SNP IGR2198a_1 was associated with susceptibility to ulcerative colitis. Homozygous carriage
both of the SNPs IGR2096a_1 and IGR2198a_1 and of the TC and IBD5 haplotype was associated with
susceptibility to ulcerative colitis. The results for heterozygous carriage all failed to achieve significance (results not
shown).
UC, ulcerative colitis.
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gastric antral Crohn’s disease, a low weight centile was
predicted by carriage of the TC haplotype (p = 0.02;
OR = 3.41 (1.20 to 9.66)) and the presence of antral
Crohn’s disease (p = 0.003; OR = 4.02 (1.58 to 10.21)).
Using a logistic regression model to compare propensity
across all 11 weight centile groupings, a very strong trend
towards higher carriage of the TC haplotype at lower weight
centiles and lower TC haplotype carriage at higher weight
centiles (p = 0.05) was apparent at Crohn’s disease diagnosis.
Homozygous carriers of the extended IBD5 risk haplotype
(patients who were homozygous mutants for all three IBD5
haplotype markers, IGR2096a_1, IGR2198a_1, and
IGR2230a_1) were more likely to lie within lower BMI
centiles and less likely to be within the highest BMI centiles
in a logistic regression model (p = 0.04).
DISCUSSION
Our data provide a series of novel and important insights into
the contribution of the IBD5 locus. We confirm a role in
determining susceptibility to early onset Crohn’s disease and
report the first evidence of association in early onset
ulcerative colitis. In addition, we have presented the first
consistent genotype–phenotype data suggesting that these
variants influence growth in both Crohn’s disease and
ulcerative colitis. We have shown that the OCTN1/2 variants
do not act independently of variants within this region in
determining susceptibility, emphasising the complexity of the
IBD5 contribution.
Perhaps the unique strengths of our study lie in the robust
phenotypic data that accompany the genetic data and in the
size of the early onset population studied. A strong
association between the IBD5 haplotype (and TC haplotype)
with low weight and body mass index at diagnosis of Crohn’s
disease is evident, with a less significant association with
height centile. The relation was demonstrated on unifactorial
and multifactorial analysis for weight centile (with the TC
haplotype) and for homozygosity for the extended IBD5
haplotype with BMI. Although the relation was most marked
in Crohn’s disease, there was a strong suggestion that it was
also present in ulcerative colitis. Given the relatively small
numbers of patients with ulcerative colitis, the study may
have been underpowered to assess this relation fully.
Our data represent perhaps the strongest to date relating
genotype to abnormal growth variables in inflammatory
bowel disease. Previous paediatric studies have tried to
correlate patient genotype with growth indices but overall
results have been not been consistent between populations.
One study has suggested variant alleles of the 2238 promoter
polymorphism in the TNFa gene protect patients from height
retardation.10 Tomer et al showed a relation between carriage
of NOD2/CARD15 variant alleles and weight below the 5th
centile (but not for height; BMI was not examined) and no
follow up data were presented.11 The data in Tomer’s study
were not subjected to multifactorial analysis; the findings
have been confounded by the strong relation between NOD2/
CARD15 carriers with ileal disease, which in turn is
associated with lower weight at diagnosis.38 Two subsequent
publications have failed to replicate these findings.9 39
In our own population, we have studied the relation of
NOD2/CARD15 genotype with growth indices; no relation
was found at diagnosis, while at follow up carriers of NOD2/
CARD15 variant alleles were more common in a low centile
band for height (2–9th) and for weight (,0.4th) only.13
There is no universally accepted definition of growth
failure or good evidence of how it should be treated.40 Growth
failure nevertheless remains a common problem, especially in
paediatric Crohn’s disease, and can persist into adult life.41
There is also evidence from prospective paediatric studies that
the growth failure is ‘‘preprogrammed’’, strongly suggesting a
genetic influence.42 Although our data do not establish that
the genotype predicts ‘‘growth failure’’—because our strongest
growth associations were with weight and BMI, not height—
they do show that genetic markers have the potential to be
used to predict growth problems, and even perhaps deter-
mine treatment strategies.
The association of markers in the IBD5 haplotype with low
anthropometric centiles signifying a more severe disease
phenotype are entirely consistent with our recent findings in
Scottish adults with Crohn’s disease.26 Possession of the
variant alleles of the TC haplotype in 374 Scottish adults with
Crohn’s disease was associated with disease progression at
follow up and, on multifactorial analysis, the need for
surgery—both phenotypic variables representing a severe
disease phenotype. As discussed in an accompanying
editorial to our paper,43 other adult datasets may also
implicate the IBD5 locus as a determinant of severe disease.
We describe a novel association of the TC haplotype with
gastric antral Crohn’s disease. Previous adult studies have
linked possession of the TC haplotype with ileal,44 colonic,25
and perianal33 Crohn’s disease, but none of these studies
considered a relation with Crohn’s disease of the proximal
gastrointestinal tract. The establishment of such a relation
gives some justification for using a phenotypic classification
of Crohn’s disease location in genotype–phenotype studies
that is more extensive than the Vienna classification—an
issue that has been intensively examined by the 2005
Montreal World congress Working Party into the classifica-
tion of IBD.29 The relation of antral disease with low weight
centile at diagnosis on multifactorial analysis is intriguing in
the light of previous prospective paediatric studies establish-
ing a link between jejunal Crohn’s disease and low weight
centile at diagnosis.8
Our data show an incidence of proximal gastrointestinal
Crohn’s disease that may appear high in comparison with
published adult series,26 but the figures are similar to the
prospective paediatric Crohn’s disease studies from Europe
and North America.8 45 The difference may in part reflect a
different disease phenotype between paediatric and adult
Crohn’s disease, but may also reflect the different investiga-
tion practices of paediatric gastroenterologists who would
regard routine upper gastrointestinal endoscopy at diagnosis
as standard practice.30
Table 8 Comparison of patients and controls who are
homozygous wild type for the IGR2198a_1 IBD5
haplotype marker single nucleotide polymorphism but
have a risk allele in the TC haplotype
Subjects with no
IBD5 risk alleles
Subjects with TC
haplotype but no
IBD5 risk alleles
Controls 82 10
IBD patients 72 5
x2 p value comparing IBD patients with controls 0.27
CD patients 47 4
x2 p value comparing CD patients with controls 0.57
UC patients 18 0
x2 p value comparing UC patients with controls 0.20
The TC haplotype does not show an independent effect on disease
susceptibility of the three IBD5 marker SNPs IGR2096a_1, IGR2198a_1,
and IGR2230a_1, examined either individually or when combined in
patients with IBD, Crohn’s disease, or ulcerative colitis compared with
controls. The data shown are only for IGR2198a_1, but results for all
SNPs were non-significant and are available on request.
CD, Crohn’s disease; IBD, inflammatory bowel disease; SNP, single
nucleotide polymorphism; UC, ulcerative colitis.
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The association between the IBD5 haplotype and suscept-
ibility to Crohn’s disease has now been clearly demonstrated
in adult studies18–21 25 26 but here we present further data from
an exclusive early onset population to replicate the findings
in Rioux’s genome-wide scan.14 Our data represent the first
paediatric study in ulcerative colitis to date and complement
adult data.18 It is noteworthy that the index study from
Canada may have been underpowered to assess the associa-
tion between IBD5 and ulcerative colitis, as it contained only
20 families with ulcerative colitis.14 Our own dataset is
considerably larger than the index study; nevertheless is
relatively small for a case–control association study, and
therefore the data have to be interpreted carefully because of
the small number of patients compared with controls. The TC
haplotype has been associated with Crohn’s disease suscept-
ibility in three adult studies,24–26 but no previous association
has been shown with ulcerative colitis. This difference may
be explained by a greater influence of the TC haplotype in
early onset disease, or may indeed reflect differing disease
phenotypes in the paediatric and adult ulcerative colitis
populations, notably the higher proportion of paediatric
patients with more extensive colitis.8 46
Despite demonstrating an association between the OCTN1/
2 variants and disease susceptibility, our data do not support
these variants as independent predictors of disease when the
IBD5 risk markers are considered. This finding is contrary to
the findings of Peltekova’s study,24 but consistent with
subsequent publications and presentations.25 26 47 48 These
apparent inconsistencies are likely to reflect the haplotype
block structure of the region as described by Daly et al (fig 1).16
The published studies to date, apart from our own studies in
the Scottish IBD population, have only examined one
haplotype marker, IGR2078a_1 (haplotype block 4), and
explored its relation (or lack of relation) with the OCTN1/2
genes (haplotype block 7).24 25 Our study examined markers
in block 4 (IGR2096a_1), block 5 (IGR2198a_1), and block 7
(IGR2230a_1), representing an extended haplotype across
the region. Thus the apparently independent effect reported
in Peltekova’s data may reflect recombination events between
haplotype block 4 and 7 in the Canadian population. This
Table 9 Genotype–phenotype of carriage rates of the TC haplotype and homozygous TC
haplotype in patients with Crohn’s disease at the time of diagnosis
TC haplotype variants
carriage rates at
diagnosis p Value
Homozygous mutant TC
haplotype carriage rates
at diagnosis p Value
Individual disease location*
Oral 79.2% v 75.3% 0.68 20.8% v 18.1% 0.75
Oesophageal 83.3% v 75.3% 0.65 50% v 15.8% 0.06
Gastric antrum 86.4% v 71.7% 0.05 36.7% v 14.2% 0.006
Gastric body 82.1% v 75.2% 0.43 14.3 % v 18.2% 0.78
Duodenal 86.9% v 74.6% 0.19 26.1% v 17.5% 0.33
Jejunal 78.6% v 76.8% 0.84 17.8% v 18.2% 0.96
Ileal 75.0% v 78.2% 0.65 23.0% v 18.2% 0.48
Caecal 75.2% v 79.3% 0.65 18.8% v 17.2% 0.84
Sigmoid 75.8% v 81.8% 0.46 22.6% v 18.2% 0.58
Rectum 77.6% v 73.7% 0.61 22.4% v 23.7% 0.86
Perianal 78.9% v 74.0% 0.46 22.5% v 22.0% 0.93
Perianal` 83.3% v 75.3% 0.59 27.8% v 22.2% 0.45
Weight ,9th centile 87.9% v 67.3% 0.002 28.8% v 16.8% 0.07
Height ,9th centile 84.1% v 68.4% ,0.05 25.0% v 21.4% 0.62
BMI ,9th centile 79.6% v 61.1% 0.02 27.8% v 16.8% 0.11
Location according to the Vienna classification28
Colonic 77.8% v 75.9% 0.80 28.9% v 21.1% 0.28
Ileal 77.8% v 76.3% 0.92 44.4% v 21.9% 0.21
Ileo-colonic 67.6% v 78.4% 0.18 17.6% v 24.3% 0.40
Upper GI 78.3% v 74.7% 0.57 20.5% v 25.3% 0.45
None1 85.7% v 76.0% 0.55 14.3% v 23.4% 1
Behaviour according to the Vienna classification28
Inflammatory 74.8% v 83.9% 0.28 22.4% v 25.8% 0.68
Stricturing 83.3% v 76.2% 0.68 16.7% v 23.3% 1
Penetrating 84.0% v 75.2% 0.33 28.0% v 22.2% 0.52
Atopic disease
Eczema 69.8% v 77.3% 0.27 15.9% v 26.1% 0.12
Asthma 73.1% v 75.4% 0.74 11.5% v 26.9% 0.02
Hayfever 72.5% v 75.9% 0.66 7.5% v 27% 0.009
All atopy 60.0% v 76.3% 0.16 0% v 25.3% 0.02
No atopy 75.6% v 74.5% 0.86 29.1% v 17.7% 0.07
The clinical features of the Crohn’s disease patients included in the study comparing carriage of the TC and
homozygous TC haplotype showing the percentage carriage of each phenotypic variable compared with the
percentage carriage of those without the phenotypic variable. The odds ratios with 95% confidence intervals for
significant results are given in the text.
*The presence or absence of evidence for Crohn’s disease activity in each location was based on evidence from
endoscopy, biopsy, or barium follow through and was independent of disease activity elsewhere in the
gastrointestinal tract (see text).
Perianal disease defined by the presence of fissures, perianal ulcers, abscesses, or fistulae but not by the presence
of skin tags alone.
`Perianal disease defined by the presence perianal ulcers, abscesses, or fistulae but not by the presence of skin
tags or fissures.
1These were patients who fulfilled the diagnostic criteria for Crohn’s disease but in whom the disease location did
not fit with the Vienna classification.
BMI, body mass index.
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issue would be best resolved by further studies in the
Canadian dataset.
Given this uncertainty about the identity of the causal gene
within the IBD5 locus it remains pertinent to examine the
role of other genes within the region: interleukin 4,49–51
interleukin 13,52 and interleukins 3 and 5, together with
GMCSF, are all plausible candidate genes within the linkage
interval.53 54 The protective association of the homozygous TC
haplotype with asthma, hayfever, and atopy would be
consistent with the evidence from genome-wide scans that
genes within the 5q31–33 region are not only important in
IBD but also in asthma and atopy.55–58 Indeed, candidate
genes within the 5q31–33 region, including IL12B gene59 and
IL13,60 have been associated with asthma and atopy.
Conclusions
In summary, we have demonstrated evidence for genetic
association between the OCTN1/2 variants within the IBD5
locus and susceptibility to inflammatory bowel disease,
Crohn’s disease, and ulcerative colitis. Of note, our study
also describes novel and consistent phenotypic associations
with low anthropometric centiles. However, the effect of the
OCTN1/2 variants is not independent of the extended IBD5
region and further investigation of these and other candidate
genes within the IBD5 linkage interval is necessary.
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An unusual cause of abdominal pain
Clinical presentation
A 39 year old man presented with right iliac fossa pain. He
had a 10 year history of intermittent abdominal pain,
diarrhoea, rectal bleeding, and orogenital ulceration.
Previous colonoscopy was normal but biopsies showed an
early indeterminate colitis. A barium follow through was
suggestive of a terminal ileal stricture and a labelled white
cell scan showed increased uptake in the right iliac fossa. A
diagnosis of ileal Crohn’s was made and he was started on
intravenous steroids.
His symptoms settled and he was discharged on oral
prednisolone and mesalazine. He subsequently had a
colonoscopy which reached into the terminal ileum and
looked normal. A week later, the pain recurred in spite of
high dose oral steroids. His abdomen was soft with no signs
of peritonism. Inflammatory markers were normal and stool
cultures were negative. He had a plain abdominal radiograph
(fig 1).
Question
What does the x ray show?
See page 1137 for answer
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Figure 1 Abdominal radiograph.
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